ストックスクリーナーアプリを入手
17.10
7.48%
1.19
プレマーケット:
16.86
-0.24
-1.40%
前日終値:
$15.91
開ける：
$16.05
24時間の取引高:
17.50M
Relative Volume:
1.67
時価総額：
$1.68B
収益：
$2.23B
当期純損益:
$-248.39M
株価収益率:
-6.3569
EPS:
-2.69
ネットキャッシュフロー:
$-697.55M
1週間 パフォーマンス:
+23.38%
1か月 パフォーマンス:
-6.25%
6か月 パフォーマンス:
-85.01%
1年 パフォーマンス:
-88.12%
1日の値動き範囲:
$15.34
$17.27
1週間の範囲:
$15.34
$19.24
52週間の値動き範囲:
$10.41
$145.00
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
名前
Sarepta Therapeutics Inc
セクター
電話
617-274-4000
住所
215 FIRST STREET, CAMBRIDGE, MA
SRPT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
17.10 | 1.56B | 2.23B | -248.39M | -697.55M | -2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 118.67B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.54 | 59.23B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
419.56 | 52.67B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
690.32 | 41.24B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
304.30 | 32.36B | 3.81B | -644.79M | -669.77M | -6.24 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-29 | アップグレード | Barclays | Underweight → Equal Weight |
| 2025-07-29 | 開始されました | Bernstein | Mkt Perform |
| 2025-07-29 | 繰り返されました | H.C. Wainwright | Sell |
| 2025-07-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2025-07-29 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-07-28 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2025-07-25 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2025-07-24 | 開始されました | Citigroup | Sell |
| 2025-07-23 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2025-07-22 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-07-21 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-07-21 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | ダウングレード | Mizuho | Outperform → Neutral |
| 2025-07-21 | ダウングレード | Needham | Hold → Underperform |
| 2025-07-21 | ダウングレード | UBS | Buy → Neutral |
| 2025-07-18 | ダウングレード | Needham | Buy → Hold |
| 2025-06-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-06-17 | 開始されました | Wolfe Research | Peer Perform |
| 2025-06-16 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-06-16 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | ダウングレード | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-04-11 | 開始されました | Wells Fargo | Overweight |
| 2025-04-02 | アップグレード | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 開始されました | Deutsche Bank | Hold |
| 2024-11-27 | 繰り返されました | Needham | Buy |
| 2024-11-25 | 開始されました | H.C. Wainwright | Sell |
| 2024-11-07 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 開始されました | Jefferies | Buy |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-07-29 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-05-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 開始されました | BMO Capital Markets | Outperform |
| 2023-12-13 | 再開されました | Citigroup | Buy |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-11-21 | 開始されました | Wedbush | Outperform |
| 2023-10-31 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-06-23 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 開始されました | SMBC Nikko | Outperform |
| 2023-04-04 | 開始されました | Citigroup | Buy |
| 2023-03-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 繰り返されました | BTIG Research | Buy |
| 2022-12-16 | アップグレード | UBS | Neutral → Buy |
| 2022-04-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 繰り返されました | Needham | Buy |
| 2021-12-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-11-05 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-09-15 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-08-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-01-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-01-11 | ダウングレード | UBS | Buy → Neutral |
| 2021-01-08 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2021-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 開始されました | Berenberg | Hold |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-08-20 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 開始されました | Mizuho | Buy |
| 2019-11-01 | 開始されました | Guggenheim | Buy |
| 2019-08-21 | 繰り返されました | Needham | Buy |
| 2019-07-09 | 繰り返されました | Morgan Stanley | Overweight |
| 2019-07-01 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-11 | 繰り返されました | Credit Suisse | Outperform |
| 2018-10-12 | 開始されました | Bernstein | Outperform |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2018-09-14 | 再開されました | BofA/Merrill | Buy |
| 2018-09-06 | 開始されました | Credit Suisse | Outperform |
| 2018-08-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 繰り返されました | Robert W. Baird | Outperform |
| 2018-06-20 | 繰り返されました | Needham | Buy |
| 2018-06-19 | 繰り返されました | H.C. Wainwright | Buy |
すべてを表示
Sarepta Therapeutics Inc (SRPT) 最新ニュース
Sarepta’s Future in Gene Therapy Remains Clouded, But Data From Partner Hansa Is a Bright Spot - MedCity News
SRPT LEGAL REMINDER: Why is Sarepta Therapeutics, Inc. Being Sued For Fraud? Investors With Losses are Reminded to Contact BFA Law by August 25 - ACCESS Newswire
Sarepta Therapeutics (SRPT) Announces Restructuring and - GlobeNewswire
Did You Lose Money on Sarepta Therapeutics, Inc. (SRPT)? Levi & Korsinsky Urges Investors to Act Before August 25, 2025 - ACCESS Newswire
SAREPTA THERAPEUTICS, INC. (NASDAQ: SRPT) SHAREHOLDER ALERT - GlobeNewswire
Sarepta to Report Q2 Earnings: What's in Store for the Stock? - TradingView
Contact The Gross Law Firm by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc.(SRPT) - Morningstar
SRPT LEGAL NOTICE: BFA Law Reminds Sarepta Therapeutics, Inc. Investors with Losses of the Imminent August 25 Securities Class Action Deadline - Newsfile
‘Unprecedented’ FDA Leaks Sow Confusion For Patients, Sarepta and Capricor - BioSpace
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT - GlobeNewswire Inc.
Investors in Sarepta Therapeutics, Inc. (SRPT): Protect Your RightsContact Levi & Korsinsky Before August 25, 2025 - ACCESS Newswire
SRPT LEGAL ALERT: Lose Money on Your Sarepta Therapeutics, - GlobeNewswire
Securities Litigation and Biotech Volatility: Sarepta Therapeutics' ELEVIDYS Crisis as a Case Study - AInvest
SRPT Investors Have the Opportunity to Lead the Sarepta Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - PR Newswire
StockWatch: As Prasad Exits FDA, Analysts See Benefit for Sarepta, CGT Stocks - Genetic Engineering and Biotechnology News
Notable analyst calls this week: Nike, Microsoft and Sarepta among top picks - Seeking Alpha
SRPT INVESTOR ALERT: Sarepta Therapeutics, Inc. Shareholders are Urged to Contact BFA Law before August 25 Class Action Deadline - Newsfile
SRPT INVESTOR REMINDER: Sarepta Therapeutics, Inc. Stock - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) Shareholders of Class Action Lawsuit and August 25, 2025 Deadline - ACCESS Newswire
Sarepta Therapeutics Inc (SRPT) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Amid FDA turmoil Sarepta’s gene therapy worries begin to ease - European Pharmaceutical Review
Untangling Sarepta’s gene therapy fallout and a growing trust deficit - Fierce Pharma
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for InvestorsContact Levi & Korsinsky - PR Newswire
Roche Slammed With Negative EMA CHMP Opinion for Sarepta’s DMD Gene Therapy Elevidys - CGTLive®
Sarepta Therapeutics, Inc. Sued for Securities Law - GlobeNewswire
SRPT INVESTOR FRAUD: Sarepta Therapeutics, Inc. Investors are Notified the Company was Sued for Fraud and to Contact BFA Law by August 25 Legal Deadline - Newsfile
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal - MSN
Sarepta Therapeutics (SRPT) Tanks 36% After 3rd Patient Death, SRPT Securities Class Action PendingHagens Berman - PR Newswire
Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results - The Globe and Mail
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Sarepta Therapeutics, Inc. LawsuitSRPT - PR Newswire
Securities Lawsuit Alert: Sarepta Therapeutics, Inc. (SRPT)Contact Levi & Korsinsky Before August 25, 2025 - ACCESS Newswire
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Barchart.com
Sarepta Therapeutics (NASDAQ:SRPT) Sees Strong Trading Volume on Analyst Upgrade - Defense World
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - GlobeNewswire
HC Wainwright Reaffirms Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT) - Defense World
FDA Gives Sarepta Green Light to Restart Shipment of DMD Gene Therapy Elevidys to Patients who are Ambulatory - CGTLive®
ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, - GlobeNewswire
SRPT INVESTOR NOTICE: BFA Law Reminds Sarepta Therapeutics, Inc. Investors to Contact the Firm before the Imminent August 25 Class Action Deadline - Newsfile
Sarepta Therapeutics, Inc. (SRPT) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of August 25, 2025 Deadline - ACCESS Newswire
Sarepta Therapeutics (SRPT) Tanks 36% After 3rd Patient - GlobeNewswire
Hospitals resume Sarepta’s gene therapy, but brace for coverage hurdles - Endpoints News
Sarepta Therapeutics (NASDAQ:SRPT) Upgraded by Barclays to “Equal Weight” Rating - Defense World
FDA’s Prasad Exits Following Political Backlash Over Sarepta - Bloomberg
FDA’s Prasad Exits Following Political Backlash Over Sarepta (3) - Bloomberg Law News
FDA vaccines head, chief medical officer Vinay Prasad departs agency - Seeking Alpha
Sarepta Therapeutics stock price target raised to $19 from $14 at Mizuho - Investing.com
Stocks making the biggest moves midday: Harley-Davidson, Wingstop, Sarepta Therapeutics and more - CNBC
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? - Benzinga
Sarepta, other Mass. biotech stocks rise on Prasad’s FDA exit - The Business Journals
Sarepta Therapeutics Inc (SRPT) 財務データ
収益
当期純利益
現金流量
EPS
3.24%
大文字化:
|
ボリューム (24 時間):